Table 2 Characteristics of the pulmonary cavities and related events
From: Pulmonary cavitation: an under-recognized late complication of severe COVID-19 lung disease
Patient 1 | Patient 2 | Patient 3 | Patient 4 | Patient 5 | Patient 6 | Patient 7 | Patient 8 | Patient 9 | Patient 10 | Patient 11 | Patient 12 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
No. of cavities (n) | 1 | 8 | 8 | 3 | 1 | 1 | 2 | 1 | 9 | 3 | 1 | 5 |
Largest cavity (mm) | 50 | 85 | 60 | 30 | 30 | 30 | 70 | 100 | 54 | 52 | 50 | 40 |
Bilateral | Y | Y | Y | Y | Y | Y | Y | |||||
Location of cavities | ||||||||||||
No. lobes with cavities (n) | 1 | 5 | 5 | 3 | 1 | 4 | 2 | 1 | 4 | 3 | 1 | 3 |
RUL | Y | Y | Y | Y | Y | Y | Y | |||||
RML | Y | Y | Y | Y | Y | |||||||
RLL | Y | Y | Y | Y | Y | Y | Y | |||||
LUL | Y | Y | Y | Y | Y | Y | Y | |||||
LLL | Y | Y | Y | Y | Y | Y | Y | |||||
Clinical events | ||||||||||||
Developed pneumothorax | Y | Y | Y | Y | ||||||||
Developed hemoptysis | Y | Y | Y | Y | ||||||||
Treated for Invasive fungal infection | Y | Y | Y | Y | Y | Y | Y | Y | ||||
Bacterial organisms in Sputum/BAL | K. pneumoniae | ECC | MRSA | S. maltophilia, C. koseri | MSSA, S. maltophilia | S. marcescens, S. maltophilia, ECC | K. pneumoniae | Acinetobacter, MRSA | ESBL K. pneumoniae, MRSA | MRSA | K. pneumoniae | |